Dovetail Genomics Launches Boston Epigenetics Society to Accelerate Vital Epigenetics and Epitranscriptomics Research, with Additional Companies in Several Developing Metropolitan Cities

0

The Boston Society’s inaugural meeting will focus on the role of epigenetics in aging and feature guest speaker David A. Sinclair, Ph.DAO and Full Professor of Genetics at Harvard Medical School

SCOTTS VALLEY, California, November 10, 2021– (BUSINESS WIRE) – Dovetail Genomics, the industry leader in advanced genomic proximity ligation solutions, today announced the creation of the Boston Epigenetics Society; a society that will meet four times a year with the aim of promoting research in epigenetics and epitranscriptomics, fostering links between academics and epigenetics scientists in industry, promoting new methods and creating a system of support for research in experimental epigenetics. The Company brings together academic and industrial partners from the greater Boston area and beyond, all sharing a passion for epigenetics.

“An essential part of Dovetail’s mission is to enable cutting-edge science and research in the field of epigenetics,” said Todd Dickinson, CEO of Dovetail Genomics. “The formation of this company, as well as those to come, will help drive this mission, spark inspiring discussion and research within the epigenetic community that will inevitably lead to new and valuable information on gene regulation. “

The Boston Epigenetics Society’s inaugural meeting takes place virtually on Tuesday, November 16 from 10:00 a.m. to 11:00 a.m. EST, and features guest speaker David A. Sinclair, Ph.DAO, professor of genetics and co-director of the Paul F. Glenn Center for research in the biology of aging at Harvard Medical School, which is widely known for its research on aging with an emphasis on epigenetics. Dr. Sinclair’s presentation, “Next Generation Epigenetics to Understand Why We Age,” will discuss the causes of aging organisms, the role of epigenetics in aging and how the aging process can be reprogrammed. The next speaker will be Robert Copeland, President, Chief Scientific Officer and Co-Founder of Accent Therapeutics, Inc.

“I am delighted to participate in the initial launch of the Boston Epigenetics Society, understanding how collaboration between academia and industry can lead to new research and therapies that might not have been discovered otherwise,” said Sinclair.

The Company’s list of founders, which range from leading pharmaceutical and therapeutic companies to notable academic institutions, currently includes: Accent Therapeutics, Alkermes, Astellas Pharma, AstraZeneca, Beth Israel Deaconess Medical Center, Broad Institute, Constellation Pharmaceuticals, Harvard Medical School, Harvard University, Massachusetts General Hospital, Ring Therapeutics, Sanofi, and University of Massachusetts School of Medicine. Additional companies for large metropolitan areas with a concentration of epigenetic and epitranscriptomic innovation are currently under development.

Details of the Boston Epigenetics Society event can be viewed here: https://bit.ly/3CMz1Pz

About dovetail genomics

Dovetail Genomics is reinventing the life sciences by opening access to genomic structure to an unparalleled level. Using Dovetail Genomics’ proprietary proximity ligation technologies, the 3D architecture of the genome is captured with primary sequence information using standard next-generation sequencing (NGS) approaches. Researchers use Dovetail Genomics’ unique methods to solve complex problems, including analysis of chromatin topology, detection of small and large structural variants, de novo chromosome assembly, haplotype phasing, and microbiome analysis in the fields of epigenetics, developmental biology, cancer research, evolutionary biology, etc. . With our assay kit services and offerings, Dovetail Genomics is ready to partner with you to elevate your genome research to a new level.

Researchers use Dovetail Genomics’ unique methods to solve complex problems, including analysis of chromatin topology, detection of small and large structural variants, de novo chromosome assembly, and phasing of haplotypes in domains. from epigenetics, developmental biology, cancer research, evolutionary biology and more. With our assay kit services and offerings, Dovetail Genomics is ready to partner with you to elevate your genome research to a new level. Dovetail Genomics is based in Scotts Valley, California. For more information about Dovetail, its technology and service offerings, visit https://dovetailgenomics.com/applications/epigenetics/gene-regulation/. Follow Dovetail on Twitter @DTGenomics.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20211110005633/en/

Contacts

Media contact
Michael sullivan
[email protected]
503-799-7520


Source link

Share.

Leave A Reply